Henlius Doses First Patient in Esophagus Cancer Drug Phase 2 Trial in China

Like
Comment
Favorite

Henlius Doses First Patient in Esophagus Cancer Drug Phase 2 Trial in China

MT Newswires Live02-10

Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase two clinical study of the HLX43 for injection in mainland China, excluding the Hong Kong, Macau, and Taiwan regions, a Monday Hong Kong bourse filing said.

The injection is an antibody-drug conjugate and targets PD-L1 with a novel DNA topoisomerase I inhibitor.

The drug is being tested for the treatment of recurrent/metastatic esophageal squamous cell carcinoma, the cancer that forms in the thin, flat cells lining the inside of the esophagus.

The company plans to further the clinical trials for the treatment of potential indications such as cervical cancer, hepatocellular carcinoma, nasopharyngeal carcinoma, head and neck squamous cell carcinoma, and non-small cell lung cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2510854574?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-02-10 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510854574","market":"nz","top_or_hot":-1,"title":"Henlius Doses First Patient in Esophagus Cancer Drug Phase 2 Trial in China","media":"MT Newswires Live","content":"<html><body><p> Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase two clinical study of the HLX43 for injection in mainland China, excluding the Hong Kong, Macau, and Taiwan regions, a Monday Hong Kong bourse filing said.</p><p>The injection is an antibody-drug conjugate and targets PD-L1 with a novel DNA topoisomerase I inhibitor.</p><p>The drug is being tested for the treatment of recurrent/metastatic esophageal squamous cell carcinoma, the cancer that forms in the thin, flat cells lining the inside of the esophagus.</p><p>The company plans to further the clinical trials for the treatment of potential indications such as cervical cancer, hepatocellular carcinoma, nasopharyngeal carcinoma, head and neck squamous cell carcinoma, and non-small cell lung cancer.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Henlius Doses First Patient in Esophagus Cancer Drug Phase 2 Trial in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHenlius Doses First Patient in Esophagus Cancer Drug Phase 2 Trial in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-10 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase two clinical study of the HLX43 for injection in mainland China, excluding the Hong Kong, Macau, and Taiwan regions, a Monday Hong Kong bourse filing said.</p><p>The injection is an antibody-drug conjugate and targets PD-L1 with a novel DNA topoisomerase I inhibitor.</p><p>The drug is being tested for the treatment of recurrent/metastatic esophageal squamous cell carcinoma, the cancer that forms in the thin, flat cells lining the inside of the esophagus.</p><p>The company plans to further the clinical trials for the treatment of potential indications such as cervical cancer, hepatocellular carcinoma, nasopharyngeal carcinoma, head and neck squamous cell carcinoma, and non-small cell lung cancer.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02696","symbol_name":"复宏汉霖","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2510854574","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510854574","pubTimestamp":1739192546,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase two clinical study of the HLX43 for injection in mainland China, excluding the Hong Kong, Macau, and Taiwan regions, a Monday Hon","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02696":"复宏汉霖","BK1161":"生物科技"},"translate_title":"复宏汉霖中国食管癌药物2期试验首例患者给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1},"content_text":"Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase two clinical study of the HLX43 for injection in mainland China, excluding the Hong Kong, Macau, and Taiwan regions, a Monday Hong Kong bourse filing said.The injection is an antibody-drug conjugate and targets PD-L1 with a novel DNA topoisomerase I inhibitor.The drug is being tested for the treatment of recurrent/metastatic esophageal squamous cell carcinoma, the cancer that forms in the thin, flat cells lining the inside of the esophagus.The company plans to further the clinical trials for the treatment of potential indications such as cervical cancer, hepatocellular carcinoma, nasopharyngeal carcinoma, head and neck squamous cell carcinoma, and non-small cell lung cancer.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}